Development of terbinafine solid lipid nanoparticles as a topical delivery system

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4409-4418

  Chen, Ying Chen ^a   Liu, Der Zen ^a   Liu, Jun Jen ^a   Chang, Tsung Wei ^a   Ho, Hsiu O ^a   Sheu, Ming Thau ^a  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Solid lipid nanoparticle; Terbinafine; Topical delivery system

Indexed keywords

ALCOHOL; CREMOPHOR; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; GLYCEROL STEARATE; LAMISIL ONCE; POLYSORBATE; SOLID LIPID NANOPARTICLE; TERBINAFINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DERMIS; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; EPIDERMIS; MICROEMULSION; MOUSE; NONHUMAN; PARTICLE SIZE; STRATUM CORNEUM;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIFUNGAL AGENTS; DERMIS; DOSAGE FORMS; DRUG CARRIERS; EPIDERMIS; GLYCERIDES; KINETICS; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NAPHTHALENES; PARTICLE SIZE; SKIN ABSORPTION; SOLUBILITY;

MUS MUSCULUS;

EID: 84870313897     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33682     Document Type: Article

References (31)

1. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharm Res. 2009;8(2):173-179.
2. Thiruganesh R, Uma Devi SK. Solid lipid nanoparticle and nanoparticle lipid carrier for controlled drug delivery-a review of state of art and recent advances. International Journal of Nanoparticles. 2010;3(1):32-52.
3. Sabadin CS, Benvegnú SA, Fontoura MMC, Saggin LMF, Tomimori J, Fischman O. Onychomycosis and tinea pedis in athletes from the State of Rio Grande Do Sul (Brazil): a cross-sectional study. Mycopathologia. 2010;171(3):183-189.
4. Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review. Expert Opin Drug Deliv. 2009;10(16):2723-2733.
5. Alberti I, Kalia YN, Naik A, Bonny JD, Guy RH. In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum. J Control Release. 2001;71(3):319-327.
6. Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv. 2010;7(11):1303-1327.
7. Gupta AK, Chow M, Daniel CR, Aly R. Treatments of tinea pedis. Dermatol Clin. 2003;21(3):431-462.
8. Robert MEM, Kalia YN. New developments in topical antifungal therapy. Am J Drug Delivery. 2006;4(4):231-247.
9. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006;173(7):707-717.
10. O'Brien TP. Therapy of ocular fungal infections. Ophthalmol Clin North Am. 1999;12(1):33-50.
11. Faergemann J, Zehender H, Denouel J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250mg terbinafine orally once per day for four weeks. Acta Derm Venereol. 1993;73(4):305-309.
12. Faergemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol. 1991; 71(4):322-326.
13. Hill S, Thomas R, Smith SG, Finlay AY. An investigation of the pharmacokinetics of topical terbinafine (Lamisil®) 1% cream. Br J Dermatol. 1992;127(4):396-400.
14. Hosseini-Yeganeh M, Andrew J, McLachlan. Tissue distribution of terbinafine in rats. J Pharm Sci. 2001;90(11):1817-1828.
15. Hosseini-Yeganeh M, McLachlan AJ. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother. 2002;46(7):2219-2228.
16. Alberti I, Kalia YN, Naik A, Guy RH. Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res. 2001;18(10):1472-1475.
17. Sch, Auml, Fer-Korting M, Schoellmann C, Korting HC. Fungicidal activity plus reservoir effect allows short treatment courses with terbinafine in tinea pedis. Skin Pharmacol Physiol. 2008;21(4):203-210.
18. Zur Mühlen A, Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie. 1998;53(8):552-555.
19. Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm. 1998;45(2):149-155.
20. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
21. Wissing SA, Müller RH. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity-in vivo study. Eur J Pharm Biopharm. 2003;56(1):67-72.
22. Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000; 49(3):211-218.
23. Lv Q, Yu A, Xi Y, etal. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009;372(1-2):191-198.
24. Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Delivery Rev. 2007;59(6):427-443.
25. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363(1-2):132-138.
26. Castro GA, Coelho ALLR, Oliveira CA, Mahecha GAB, Oréfice RL, Ferreira LAM. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm. 2009;381(1):77-83.
27. Sachdeva V, Siddoju S, Yu YY, Kim HD, Friden PM, Banga AK. Transdermal iontophoretic delivery of terbinafine hydrochloride: Quantitation of drug levels in stratum corneum and underlying skin. Int J Pharm. 2010;388(1-2):24-31.
28. Repka MA, Mididoddi PK, Stodghill SP. Influence of human nail etching for the assessment of topical onychomycosis therapies. Int J Pharm. 2004;282(1-2):95-106.
29. Vaka SRK, Murthy SN, O'Haver JH, Repka MA. A platform for predicting and enhancing model drug delivery across the human nail plate. Drug Dev Ind Pharm. 2011;37(1):72-79.
30. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Delivery Rev. 2004;56(5):675-711.
31. Wissing SA, Müller RH. Solid lipid nanoparticles (SLN): a novel carrier for UV blockers. Pharmazie. 2001;56(10):783-786.